Activin-A Overexpression in the Murine Lung Causes Pathology That Simulates Acute Respiratory Distress Syndrome
- 15 February 2012
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 185 (4), 382-391
- https://doi.org/10.1164/rccm.201105-0784oc
Abstract
Activin-A is up-regulated in various respiratory disorders. However, its precise role in pulmonary pathophysiology has not been adequately substantiated in vivo. To investigate in vivo the consequences of dysregulated Activin-A expression in the lung and identify key Activin-A-induced processes that contribute to respiratory pathology. Activin-A was ectopically expressed in murine lung, and functional, structural, and molecular alterations were extensively analyzed. The validity of Activin-A as a therapeutic target was demonstrated in animals overexpressing Activin-A or treated with intratracheal instillation of LPS. Relevancy to human pathology was substantiated by demonstrating high Activin-A levels in bronchoalveolar lavage (BAL) samples from patients with acute respiratory distress syndrome (ARDS). Overexpression of Activin-A in mouse airways caused pulmonary pathology reminiscent of acute lung injury (ALI)/ARDS. Activin-A triggered a lasting inflammatory response characterized by acute alveolar cell death and hyaline membrane formation, sustained up-regulation of high-mobility group box 1, development of systemic hypercoagulant state, reduction of surfactant proteins SpC, SpB, and SpA, decline of lung compliance, transient fibrosis, and eventually emphysema. Therapeutic neutralization of Activin-A attenuated the ALI/ARDS-like pathology induced either by ectopic expression of Activin-A or by intratracheal instillation of LPS. In line with the similarity of the Activin-A-induced phenotype to human ARDS, selective up-regulation of Activin-A was found in BAL of patients with ARDS. Our studies demonstrate for the first time in vivo the pathogenic consequences of deregulated Activin-A expression in the lung, document novel aspects of Activin-A biology that provide mechanistic explanation for the observed phenotype, link Activin-A to ALI/ARDS pathophysiology, and provide the rationale for therapeutic targeting of Activin-A in these disorders.This publication has 37 references indexed in Scilit:
- The Acute Respiratory Distress Syndrome: Pathogenesis and TreatmentAnnual review of pathology, 2011
- Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway diseaseThe Journal of Experimental Medicine, 2009
- Acute Lung Injury ReviewInternal Medicine, 2009
- The glycoprotein-hormones activin A and inhibin A interfere with dendritic cell maturationReproductive Biology and Endocrinology, 2008
- Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemiaProceedings of the National Academy of Sciences of the United States of America, 2007
- The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factorThorax, 2007
- Activin A Suppresses Neuroblastoma Xenograft Tumor Growth via Antimitotic and Antiangiogenic MechanismsCancer Research, 2005
- Activin: an important regulator of wound repair, fibrosis, and neuroprotectionMolecular and Cellular Endocrinology, 2004
- The Plasmacytoma Growth Inhibitor Restrictin-P Is an Antagonist of Interleukin 6 and Interleukin 11Online Journal of Public Health Informatics, 1995
- Modulation of Growth of Vascular Smooth Muscle Cells by Activin AExperimental Cell Research, 1993